RECRUITING

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Description

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Conditions

ObesityVascular Health
Talk to us

Related Conditions:

ObesityVascular Health

Study Overview

On this page

Study Details

Study overview

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Columbia

Harry S. Truman Memorial, Columbia, MO, Columbia, Missouri, United States, 65201-5275

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body mass index (BMI) 30-45 kg/m2
  • * 30-60 years of age at randomization
  • * Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030)
  • * Unable to provide consent
  • * Diabetes mellitus
  • * Uncontrolled hypertension (\>180/90mmHg) or systolic \<100mmHg at screening visit
  • * Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
  • * Diagnosis of chronic kidney disease
  • * Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • * Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
  • * Use of GLP-1 analogs or SGLT2 inhibitors
  • * Use of hormone replacement therapy
  • * Use of pharmacological therapy for weight loss
  • * Body weight changes \>10% within the past 6 months
  • * History of hypersensitivity to nitrates
  • * History of ketoacidosis
  • * History of recurrent UTIs or mycotic genital infections
  • * Use of anticoagulants
  • * Change in anti-hypertensive medication regimen (if in use) during the last 90 days
  • * Pregnancy

Ages Eligible for Study

30 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

VA Office of Research and Development,

Jaume Padilla Parellada, PhD, PRINCIPAL_INVESTIGATOR, Harry S. Truman Memorial, Columbia, MO

Study Record Dates

2029-12-31